<?xml version="1.0"?>
<rss version="2.0">
  <channel>
    <title>RxPG News : Gastric Cancer</title>
      <link>http://www.rxpgnews.com/</link>
      <description>Medical News and Information</description>
      <pubDate>Thu, 21 Aug 2008 02:00:28 PST</pubDate>
      <language>en-us</language>
      <item>
        <title>Genetic mutations identified for type of gastric cancer</title>
        <link>http://www.rxpgnews.com/research/Genetic-mutations-identified-for-type-of-gastric-cancer_37933.shtml</link>
        <category>Latest Research</category>
        <description>Researchers have identified novel genetic mutations that are linked to hereditary diffuse gastric cancer, with these mutations being due to both independent mutational events and common ancestry, according to a study in the June 6 issue of JAMA. This study is being released early to coincide with its presentation at the annual meeting of the American Society of Clinical Oncology.</description>
        <pubDate>Tue, 05 Jun 2007 04:00:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/research/Genetic-mutations-identified-for-type-of-gastric-cancer_37933.shtml</guid>
      </item>
      <item>
        <title>Less than one third gastric cancer patients actually have adequate lymph node assessments</title>
        <link>http://www.rxpgnews.com/gastriccancer/Less_than_one_third_gastric_cancer_patients_actual_4991_4991.shtml</link>
        <category>Gastric Cancer</category>
        <description>Most patients who undergo gastric cancer staging by lymph node sampling have inadequate assessments that compromise survival, according to a new study. Published in the November 1, 2006 issue of CANCER , a peer-reviewed journal of the American Cancer Society, the study reveals that less than one third of gastric cancer patients had adequate lymph node assessments (ALNA). </description>
        <pubDate>Mon, 25 Sep 2006 18:38:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/gastriccancer/Less_than_one_third_gastric_cancer_patients_actual_4991_4991.shtml</guid>
      </item>
      <item>
        <title>Long term benefits of Imatinib in advanced gastrointestinal stromal tumors (GIST) confirmed</title>
        <link>http://www.rxpgnews.com/gastriccancer/Long_term_benefits_of_Imatinib_in_advanced_gastroi_4375_4375.shtml</link>
        <category>Gastric Cancer</category>
        <description>People with advanced gastrointestinal stromal tumors (GIST) who take Gleevec (imatinib) for prolonged periods continue to benefit from the drug, according to a five-year study by Oregon Health &amp;amp; Science University Cancer Institute researchers.</description>
        <pubDate>Mon, 05 Jun 2006 16:37:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/gastriccancer/Long_term_benefits_of_Imatinib_in_advanced_gastroi_4375_4375.shtml</guid>
      </item>
      <item>
        <title>New discoveries to tackle stomach cancer</title>
        <link>http://www.rxpgnews.com/gastriccancer/New_discoveries_to_tackle_stomach_cancer_3567_3567.shtml</link>
        <category>Gastric Cancer</category>
        <description>A research team has come up with a molecular map and other discoveries to help develop better treatment for stomach cancer, which is common in Asians, researchers said Friday.</description>
        <pubDate>Fri, 03 Mar 2006 12:55:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/gastriccancer/New_discoveries_to_tackle_stomach_cancer_3567_3567.shtml</guid>
      </item>
      <item>
        <title>Stomach cancer formation can be supressed by by lowering Stat3 hyperactivity</title>
        <link>http://www.rxpgnews.com/gastriccancer/Stomach_cancer_formation_can_be_supressed_by_by_lo_1924_1924.shtml</link>
        <category>Gastric Cancer</category>
        <description>It started several years ago with the observation that a large group of seemingly unconnected genes were behaving differently in patients with stomach cancer. Now a multi-national research team led by the Melbourne Branch of the Ludwig Institute for Cancer Research (LICR) has joined the proverbial dots and identified a potential new target for stomach cancer therapy, according to a paper published today in the prestigious Nature Medicine journal.</description>
        <pubDate>Mon, 25 Jul 2005 17:30:00 PST</pubDate>
        <guid isPermaLink="true">http://www.rxpgnews.com/gastriccancer/Stomach_cancer_formation_can_be_supressed_by_by_lo_1924_1924.shtml</guid>
      </item>


  </channel>
</rss>
